Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects.

Source: Clinical and Molecular Allergy - June 16, 2021 Category: Allergy & Immunology Authors: Eustachio Nettis, Lucia Masciopinto, Elisabetta Di Leo, Nicola De Candia, Marcello Albanesi, Danilo Di Bona, Nicola Quaranta and Luigi Macchia Tags: Case Report Source Type: research